Alpha Teknova launched the latest serotype-specific version of their proprietary AAV-Tek AEX Buffer Screening Kit for AAV6, along with a suite of reagents to support every step of the plasmid production workflow. All products are available for purchase starting today. “Our team is relentlessly focused on developing solutions that specifically address the needs of our customers. Our latest products demonstrate our focus on addressing key bioprocessing bottlenecks and manufacturing inefficiencies during process development,” said Stephen Gunstream, Teknova’s President and Chief Executive Officer. “We’re committed to fulfilling our goal of becoming a true single-source partner for our customers across multiple AAV gene therapy constructs and related industry workflows. With today’s launch of our AAV-Tek AEX Buffer Screening Kit for AAV6, we now support three different serotypes during downstream processing, with more to come. In addition, we offer more than 60 off-the-shelf reagents to help expedite plasmid production and purification. By making it fast and easy to get the exact solution they need at every step along the way, our customers are able to focus on the science and get into the clinic faster.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TKNO:
- Insiders Pour Millions Into These 2 Beaten-Down Stocks, Analysts Say They Could Be Ready to Bounce Back — Here’s Why You Should Take Notice
- Teknova Announces Closing of $22.9 Million Concurrent Registered Direct Offering and Private Placement and Amends Credit Facility
- Alpha Teknova to sell 1.086M shares at $1.85 in registered direct offering
- Alpha Teknova appoints Demski as new board member
- Alpha Teknova cuts FY23 revenue view to $37M-$40M from $42M-$46M